Drug intelligence / Profile preview

MESO-HSS1

Development stage: Preclinical
Lead developer: Memorial Sloan Kettering Cancer Center
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MESO-HSS1 is a full-length human IgG monoclonal antibody targeting mesothelin (MSLN), a cell-surface glycoprotein overexpressed in various malignancies including pancreatic, ovarian, and lung cancers. Developed primarily as an immunoPET imaging agent, MESO-HSS1 can be radiolabeled (e.g., with Zirconium-89) or used in pretargeting strategies (e.g., using TCO-Tz click chemistry) to detect mesothelin-positive tumors. Research indicates it is effective for imaging even in low-mesothelin-expressing cancer lines like H596, showing high tumor-to-organ ratios, particularly in pancreatic cancer models.

Targets

Mesothelin

Beyond the preview

Go deeper on MESO-HSS1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MESO-HSS1.

Explore the full profile